Anti-Fbibrosis Agent Development
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 31 May 2026
Special Issue Editor
Interests: medicinal chemistry; drug discovery and development; pharmaceutical chemistry; Alzheimer’s disease; anti-fibrotic drug; anti-tumor agents; anti-inflammatory compounds; protein–protein interaction inhibitors
Special Issue Information
Dear Colleagues,
Idiopathic pulmonary fibrosis (IPF) is a disease characterized by unknown causes of inflammation occurring in the alveoli, followed by progressive fibrosis that leads to stiffening of the lungs and ultimately results in loss of pulmonary function. More than 50% of patients die within 2~3 years after diagnosis, and there are no effective treatments available. The development of anti-fibrotic agents is a rapidly evolving field focused on halting or reversing this process. The traditional approach has been to treat the underlying cause (e.g., antivirals for hepatitis), but there is a critical need for drugs that directly target the fibrotic pathway itself.
Consequently, efforts to develop novel anti-fibrotic therapeutics have been actively undergoing. In this Special Issue, we aim to review the current status of therapeutic development for (pulmonary) fibrosis and provide insights that may accelerate the discovery of new treatment options. This Special Issue aims to provide a comprehensive overview of the current landscape and future potential of anti-fibrosis agents in idiopathic pulmonary fibrosis. We welcome high-quality contributions that will foster scientific discussion and innovation in this rapidly evolving field.
Prof. Dr. Younghwa Na
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- idiopathic pulmonary fibrosis (IPF)
- anti-fibrosis
- drug discovery
- combination therapies
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
